Electromed (ELMD) Q4 2024 earnings summary

Executive summary

• Achieved record quarterly and annual revenues for the third consecutive quarter and full year, with Q4 net revenue of $14.8 million (up 9% year-over-year) and full-year revenue of $54.7 million (up 14%).

• Operating income reached record levels: $2.3 million for Q4 (up 56.3%) and $6.6 million for the year (up 64.2%), reflecting improved operating leverage.

• Net income for fiscal 2024 was $5.2 million ($0.58 per diluted share), up 62.7% from $3.2 million ($0.36 per share) in 2023.

• Cash position exceeded $16 million at year-end, with no debt and strong working capital of $36.5 million.

• Gained market share through infrastructure investments and market development initiatives, despite headwinds from the expiration of the CMS waiver.

Financial highlights

• Direct home care segment revenue grew 12.6% year-over-year to $49.5 million, representing 90% of total revenue.

• Hospital revenue increased 21.9% to $2.5 million; home care distributor revenue rose 14.5% to $1.9 million.

• Gross profit was $41.7 million (76.3% of net revenues), up from $36.5 million (76%) last year.

• SG&A expenses increased 9.2% to $34.5 million, mainly due to higher compensation and sales support.

• Homecare revenue per direct sales rep was $967,000, above the annual target range.

Outlook and guidance

• Plans to expand the sales team to 57 reps and increase regional managers to 7 by year-end 2025.

• Upgraded sales incentive plan expected to drive improved sales results.

• Fiscal 2025 home care revenue per rep guidance raised to $900,000–$1 million.

• Management expects continued double-digit top-line growth and expanded operating leverage, supported by ongoing investments in growth and market development.